QUOTE AND NEWS
Motley Fool  Jul 19  Comment 
They're both promising names in the red-hot oncology space. But which stock is the better buy right now?
newratings.com  Jul 18  Comment 
LONDON (dpa-AFX) - ViiV Healthcare presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with...
Motley Fool  Jun 17  Comment 
These stocks fell on a flat day for the market. Find out why.
Reuters  Jun 17  Comment 
* Outcomes of strategic review includes significant reduction in company's expense base
Benzinga  Jun 17  Comment 
  GlycoMimetics Inc (NASDAQ: GLYC) shares fell 18.69 percent to $5.99. GlycoMimetics priced public offering of 3.3 million shares at $6.10 per share. Innocoll Holdings PLC (NASDAQ: INNL) shares declined 14.90 percent to $6.26....
Benzinga  Jun 17  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) revealed the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the Food and Drug Administration. The company is...
newratings.com  Jun 17  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals Inc. (ARIA) announced that it has completed two distribution agreements for Iclusig (ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company...
Benzinga  Jun 13  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) revealed long-term follow-up data from its pivotal Phase 2 PACE clinical study of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid...
Motley Fool  Jun 9  Comment 
May was full of good news for Ariad, but it's not out of the weeds quite yet.
newratings.com  Jun 6  Comment 
WASHINGTON (dpa-AFX) - ARIAD Pharmaceuticals, Inc. (ARIA) announced updated clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease...




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki